[Practical questions on therapy with new antithrombotic agents]

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• New peroral anticoagulants (NPA) and antiplatelet agents have emerged as significant advancements in antithrombotic therapy.
• Traditional agents like warfarin and clopidogrel have limitations, including genetic variability affecting efficacy and metabolic conversion issues.

Purpose of the Study:

• To evaluate the efficacy and safety of novel peroral antithrombotic agents compared to existing treatments.
• To review clinical outcomes and guideline recommendations for new anticoagulants and antiplatelet drugs.

Main Methods:

• Review of pilot studies (RE-LY, ROCKET AF, ARISTOTLE, PLATO, TIMI 38 TRITON) and subsequent clinical experiences.
• Analysis of comparative data on stroke, systemic embolism, and bleeding events.
• Examination of genetic factors influencing clopidogrel metabolism and resistance.

Main Results:

• NPA (dabigatran, rivaroxaban, apixaban) demonstrated non-inferiority and, in some cases, superiority in preventing stroke and embolism.
• Apixaban and dabigatran showed superiority in reducing bleeding events at specific dosages.
• New antiplatelet agents (ticagrelor, prasugrel) offer faster onset and reduced resistance compared to clopidogrel.
• Ticagrelor demonstrated mortality benefits in acute coronary syndrome and chronic kidney disease patients, despite increased bleeding risks.

Conclusions:

• New antithrombotic agents represent a significant improvement in managing thrombotic complications.
• Guidelines increasingly favor NPA over warfarin for most patients.
• Further clinical research is needed to optimize antithrombotic therapy selection.